No Increase in Incidence or Risk of Recurrence of Breast Cancer in Ospemifene-Treated Patients with Vulvovaginal Atrophy (VVA)

Vulvovaginal atrophy (or VVA), part of the genitourinary syndrome of menopause (GSM), is a condition that develops in an estrogen-deficient setting that affects peri-and post-menopausal women causing several distressing urogenital symptoms including dryness, reduced lubrication, itching, burning, irritable bladder symptoms and painful intercourse [1,2]. An estimated 50% of postmenopausal women will experience symptoms of VVA [1], greatly impacting their quality of life [1,3]. Treatment for VVA consist of over the counter lubricants, moisturizers or vaginal prescription estrogen therapies, and prescription dehydroepiandrosterone (DHEA) [3 –5], however their use is reported in less than half of the VVA patients [3].

Source: Maturitas - July 9, 2020 Category: Primary Care Authors: Bin Cai, James Simon, Paola Villa, Nicoletta Biglia, Nicholas Panay, Stora Djumaeva, Martire Particco, Hemanth Kanakamedala, Corrado Altomare Source Type: research